Literature DB >> 35066293

Timing of cannabis exposure relative to prodrome and psychosis onset in a community-based first episode psychosis sample.

Emily R Kline1, Maria Ferrara2, Fangyong Li2, Deepak Cyril D'Souza2, Matcheri Keshavan3, Vinod H Srihari2.   

Abstract

Cannabis has been implicated as both a potential cause and adverse prognostic factor in psychotic disorders. Investigating the contributory role of cannabis toward the overall burden of psychotic illnesses may represent an important step toward psychosis prevention and treatment. The current study samples consecutive admissions (N = 246) to two community based first-episode psychosis services to characterize timing of cannabis use relative to psychosis and attenuated symptom onset, differences between those with and without cannabis exposure, and the association of age at first cannabis exposure with clinical and demographic variables. Both cannabis exposure (78%) and cannabis use disorders (47%) were highly prevalent at admission. In 94% of participants, cannabis use preceded the onset of both attenuated and full-threshold psychosis symptoms by several years. Earlier age at first exposure to cannabis was associated with younger age at prodrome and psychosis onset, worse premorbid functioning, and greater severity of cannabis use disorder at admission. The timing of first exposure to cannabis may have individual prognostic as well as public health significance. Documenting the prevalence and impact of cannabis use in early psychosis samples, as well as the overall incidence of psychotic disorders, will be of vital public health significance as the United States enacts cannabis legalization and cannabis products become more widely available.
Copyright © 2022 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cannabis; First episode psychosis; Marijuana; Prodrome; Schizophrenia

Mesh:

Year:  2022        PMID: 35066293      PMCID: PMC8882157          DOI: 10.1016/j.jpsychires.2022.01.039

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  44 in total

Review 1.  Cannabis use and transition to psychosis in individuals at ultra-high risk: review and meta-analysis.

Authors:  T Kraan; E Velthorst; L Koenders; K Zwaart; H K Ising; D van den Berg; L de Haan; M van der Gaag
Journal:  Psychol Med       Date:  2015-11-16       Impact factor: 7.723

2.  Prevalence and correlates of alcohol and cannabis use disorders in the United States: results from the national longitudinal study of adolescent health.

Authors:  Brett C Haberstick; Susan E Young; Joanna S Zeiger; Jeffrey M Lessem; John K Hewitt; Christian J Hopfer
Journal:  Drug Alcohol Depend       Date:  2013-12-14       Impact factor: 4.492

3.  Neurodevelopmental liability to schizophrenia: the complex mediating role of age at onset and premorbid adjustment.

Authors:  X Goldberg; M Fatjó-Vilas; R Penadés; S Miret; M J Muñoz; H Vossen; L Fañanás
Journal:  Schizophr Res       Date:  2011-10-12       Impact factor: 4.939

Review 4.  Cannabis use in first episode psychosis: Meta-analysis of prevalence, and the time course of initiation and continued use.

Authors:  Hannah Myles; Nicholas Myles; Matthew Large
Journal:  Aust N Z J Psychiatry       Date:  2015-08-18       Impact factor: 5.744

5.  Tobacco and Marijuana Use Among US College and Noncollege Young Adults, 2002-2016.

Authors:  Satomi Odani; Biesse D Soura; Michael A Tynan; Rene Lavinghouze; Brian A King; Israel Agaku
Journal:  Pediatrics       Date:  2019-11-11       Impact factor: 7.124

6.  Predictive validity of conversion from the clinical high risk syndrome to frank psychosis.

Authors:  Laura A Yoviene Sykes; Maria Ferrara; Jean Addington; Carrie E Bearden; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Diana O Perkins; Daniel H Mathalon; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Thomas H McGlashan; Kristen A Woodberry; Albert R Powers; Allison N Ponce; John D Cahill; Jessica M Pollard; Vinod H Srihari; Scott W Woods
Journal:  Schizophr Res       Date:  2019-12-19       Impact factor: 4.939

7.  Too young for Cannabis? Choice of minimum legal age for legalized non-medical Cannabis in Canada.

Authors:  Hai V Nguyen; Stephen Bornstein; John-Michael Gamble; Maria Mathews; Lisa Bishop; Shweta Mital
Journal:  BMC Public Health       Date:  2020-05-14       Impact factor: 3.295

8.  What Causes the Onset of Psychosis in Individuals at Clinical High Risk? A Meta-analysis of Risk and Protective Factors.

Authors:  Dominic Oliver; Thomas J Reilly; Ottone Baccaredda Boy; Natalia Petros; Cathy Davies; Stefan Borgwardt; Philip McGuire; Paolo Fusar-Poli
Journal:  Schizophr Bull       Date:  2020-01-04       Impact factor: 9.306

9.  The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study.

Authors:  Marta Di Forti; Diego Quattrone; Tom P Freeman; Giada Tripoli; Charlotte Gayer-Anderson; Harriet Quigley; Victoria Rodriguez; Hannah E Jongsma; Laura Ferraro; Caterina La Cascia; Daniele La Barbera; Ilaria Tarricone; Domenico Berardi; Andrei Szöke; Celso Arango; Andrea Tortelli; Eva Velthorst; Miguel Bernardo; Cristina Marta Del-Ben; Paulo Rossi Menezes; Jean-Paul Selten; Peter B Jones; James B Kirkbride; Bart Pf Rutten; Lieuwe de Haan; Pak C Sham; Jim van Os; Cathryn M Lewis; Michael Lynskey; Craig Morgan; Robin M Murray
Journal:  Lancet Psychiatry       Date:  2019-03-19       Impact factor: 77.056

10.  Association Between Continued Cannabis Use and Risk of Relapse in First-Episode Psychosis: A Quasi-Experimental Investigation Within an Observational Study.

Authors:  Tabea Schoeler; Natalia Petros; Marta Di Forti; Jean-Baptiste Pingault; Ewa Klamerus; Enrico Foglia; Amanda Small; Robin Murray; Sagnik Bhattacharyya
Journal:  JAMA Psychiatry       Date:  2016-11-01       Impact factor: 21.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.